Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Share-based Compensation (2016 - 2025)

Spyre Therapeutics' Share-based Compensation history spans 11 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 6.26% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $28.4 million, down 36.57%, while the annual FY2025 figure was $37.6 million, 16.1% down from the prior year.
  • Share-based Compensation reached $9.8 million in Q4 2025 per SYRE's latest filing, up from $9.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $17.3 million in Q4 2023 to a low of $200000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $5.8 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 1110.58% in 2023, then tumbled 97.7% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $2.1 million in 2021, then tumbled by 31.85% to $1.4 million in 2022, then skyrocketed by 1110.58% to $17.3 million in 2023, then crashed by 46.55% to $9.2 million in 2024, then grew by 6.26% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Share-based Compensation are $9.8 million (Q4 2025), $9.6 million (Q3 2025), and $200000.0 (Q2 2025).